Welcome to PGIM. This page is intended for Institutional Investors. Change your role here.
You are attested as a Financial Advisor / Intermediary, but this page is intended for an Institutional Investor. Change your role here.
You are attested as a Borrower, but this page is intended for an Institutional Investor. Change your role here.
You are attested as an Individual Investor, but this page is intended for an Institutional Investor. Change your role here.
You are attested as a Financial Advisor / Intermediary, but this page is intended for an Institutional Investor.
You are attested as a Borrower, but this page is intended for an Institutional Investor.
You are attested as an Individual Investor, but this page is intended for an Institutional Investor.
Access to medicine is a vital issue at the crossroads of global health issue, corporate responsibility, and ESG investing. Join us as we unpack barriers to equitable access, explore how pharmaceutical companies and ESG-focused investors are addressing these challenges, the emergence of patient reach is as a measure of progress, and how improvements in reporting can align access initiatives with business models to drive both sustainable growth and social impact.
Birgit Lundem Jakobsen, ESG Specialist at PGIM, hosts this discussion with Bram Wagner, Investor Engagement Lead for the Access to Medicine Foundation, and Hank Balbirer, CFA, U.S. Investment Grade Senior Credit Research Analyst at PGIM.
Recorded on November 5, 2025.
Let us help you navigate today's complex market environment.
PGIMはお客様からの信頼を大切にし、プライバシーを尊重しています。当社は、お客様の利便性を向上させるためにクッキーを使用しています。クッキー設定の管理や、当社による情報保護の取り組みについての詳細は、PGIMプライバシーセンターでご確認いただけます。
*This website uses cookies
PGIMはお客様からの信頼を大切にし、プライバシーを尊重しています。当社は、お客様の利便性を向上させるためにクッキーを使用しています。クッキー設定の管理や、当社による情報保護の取り組みについての詳細は、PGIMプライバシーセンターでご確認いただけます。
This field is required.
Loading terms...
Terms and Conditions could not be loaded. Please contact your system administrator.